Welcome to the News From ECOG-ACRIN blog; COVID-19 month six reflections; clinical trial enrollment continues to improve; EA Cancer Research Advocates Committee adds five new members
This phase II trial by EA's Cancer Control and Survivorship Committee is comparing two promising pneumonitis treatments for patients receiving PD-1/PD-L1 therapy
A second interim analysis of this international adjuvant study for HR+, HER2- early breast cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence
Up to eight young investigators will present their work at the annual Young Investigator Symposium, taking place during the Virtual Fall 2020 Group Meeting
This is the only study that is currently designed to test the ability to improve long-term outcomes by refining early-setting triple-negative breast cancer chemotherapy without exposing ALL patients to more toxicity preoperatively
In the fifth month of restrictions due to COVID-19, member institutions pivot back to focus on general health care; clinical trial enrollments begin to rise back up to pre-pandemic levels; Fall 2020 Group Meeting to be virtual; EA holds first meeting of planned move to an anti-racist agenda
Strong EA research presence at ASCO 2020; the horrific killing of George Floyd; health equity and diversity in the field of oncology; the need for EA to participate in changing a specifically anti-racist culture and increase diversity and inclusion